DIAGNOSIS AND TREATMENT OF HYPERTENSION IN PREGNANCY

Erica Giwa, MD, FACOG

Medical Director, Obstetrics and Gynecology

Texas Children's Health Plan, The Center for Children and Women


OBJECTIVES

- Overview of Pregnancy Medical Home Model
- Review diagnostic criteria of hypertensive spectrum in pregnancy
- Discuss collaborative management of patients
- Review 4th trimester management of hypertensive patients

WHAT IS A MEDICAL HOME?

A model of primary care that is patient – centered, comprehensive, team – based, coordinated, accessible, and focused on quality and safety. Hallmarks of the medical home are:

- Increased access to care
- Multiple locations
- Team based approach
- Multiple service lines under one roof



Services


- Obstetrics/Gynecology
- Pediatrics
- Behavioral Health
- Optometry
- Dentistry
- Radiology
- Pathology
- Pharmacy
- Speech Therapy

Team Members


- Physicians
- Certified Nurse Midwives
- Psychologists
- Pharmacists
- Registered Nurses
- Medical Assistants
- Clinical Therapists
- Social Workers
- Nutritionists
- Health Educators
- Others



MEDICAL HOME



What Goes Into Your Health?




IMPACT OF THE MEDICAL HOME




- √ ED visits
- √ Hospitalizations
- ✓ Per member per month costs
- ✓ Readmissions following discharge
- √ Length of stay

MATERNAL MORTALITY IN THE US

- The United States has the highest maternal mortality among developed nations
- Maternal mortality in Texas and specifically in Harris County in unacceptably high
 - 14.6 -18.6 deaths/ 100,000




CAUSES OF MATERNAL MORTALITY




INFANT MORTALITY IN US

U.S. surpassed by Singapore

The infant mortality rate (deaths per 1,000 live births) used to be much higher in Singapore than in the U.S. Now it is the reverse, and the U.S. and the Russian rates are nearly the same.




Source: World Bank Open Data



Source: NYSDOH Vital Records; Analysis by the Monroe County Department of Public Health and Common Ground Health



MATERNAL MORTALITY DOESN'T JUST HAPPEN



THE PROBLEM

- Leading cause of maternal and perinatal morbidity
 - In the U.S. 12% of maternal deaths are attributable to preeclampsia and eclampsia
- Occurs in 5-10% pregnancies worldwide
- Accounts for 15% of preterm births in the U.S.
- Infants born to mothers with pre-eclampsia are at increased risk of growth restriction, NICU admission and neonatal death
- In 2012, the cost of preeclampsia within the first 12 months of delivery was
 \$2.18 billion in the United States

WHAT NOW?



- Previous c section
- Depression
- GDM in previous pregnancy
- Elevated Blood pressure
- Twins

RECOGNIZE THE RISK FACTORS

Box 1. Risk Factors for Preeclampsia

Nulliparity

Multifetal gestations

Preeclampsia in a previous pregnancy

Chronic hypertension

Pregestational diabetes

Gestational diabetes

Thrombophilia

Systemic lupus erythematosus

Prepregnancy body mass index greater than 30

Antiphospholipid antibody syndrome

Maternal age 35 years or older

Kidney disease

Assisted reproductive technology

Obstructive sleep apnea

ACOG Practice Bulletin, Number 202







LOW-DOSE ASPIRIN USE FOR THE PREVENTION OF MORBIDITY AND MORTALITY FROM PREECLAMPSIA CLINICAL SUMMARY OF U.S. PREVENTIVE SERVICES TASK FORCE RECOMMENDATION

Population	Asymptomatic pregnant women who are at high risk for preeclampsia				
Recommendation	Prescribe low-dose (81 mg/d) aspirin after 12 weeks of gestation. Grade: B				
Risk Assessment	Descript warmen are at the horizontal procedure risk for preceduring if they have 4 are more of the fallowing view factors.				
Nisk Assessment	Pregnant women are at high risk for preeclampsia if they have 1 or more of the following risk factors: History of preeclampsia, especially when accompanied by an adverse outcome Multifetal gestation Chronic hypertension Type 1 or 2 diabetes Renal disease Autoimmune disease (i.e., systemic lupus erythematosus, the antiphospholipid syndrome)				
Preventive Medication	Low-dose aspirin (60 to 150 mg/d) initiated between 12 and 28 weeks of gestation reduces the occurrence of preeclampsia, preterm birth, and ISSR in women at increased risk for preeclampsia.				
	The harms of low-dose aspirin in pregnancy are considered to be no greater than small.				
Balance of Benefits and Harms	There is a substantial net benefit of daily low-dose aspirin to reduce the risk for preeclampsia, preterm birth, and IUGR in women at high risk for preeclampsia.				
Other Relevant USPSTF Recommendations	The USPSTF recommends that all women planning or capable of pregnancy take a daily supplement containing 0.4 to 0.8 mg (400 to 800 µg) of folic acid. This recommendation is available at www.uspreventiveservicestaskforce.org.				

MAKE THE DIAGNOSIS



RESOURCES



GESTATIONAL HYPERTENSION

- SBP > or = 140 **OR** DBP > or = 90 on two occasions at least 4 hours apart
- Greater than 20 weeks gestation
- Previously normal blood pressure

AND

- No proteinuria
- No symptoms
- No laboratory abnormalities



MILD PRE-ECLAMPSIA

+

SEVERE PRE - ECLAMPSIA

PRE – ECLAMPSIA W/O SEVERE FEATURES

- SBP > or = 140 **OR** DBP > or = 90 on two occasions at least 4 hours apart
- Greater than 20 weeks gestation
- Previously normal blood pressure

AND

- Positive proteinuria
- No symptoms
- No laboratory abnormalities

PRE – ECLAMPSIA WITH SEVERE FEATURES

- SBP > or = 160 **OR** DBP > or = 110 on two occasions at least 4 hours apart
- Greater than 20 weeks gestation
- Previously normal blood pressure

AND

Positive proteinuria

OR

- New Onset
 - Thrombocytopenia

- Renal insufficiency
- Cerebral or visual disturbances

- Elevated LFTS

- RUQ pain

- Pulmonary Edema

CHRONIC HYPERTENSION

- Hypertension diagnosed:
 - Before pregnancy
 - Before 20 weeks gestation
 - During pregnancy for the first time that doesn't resolve during the postpartum period (12 weeks)

SUPERIMPOSED PRE-ECLAMPSIA

- Sudden increase in BP that was initially well controlled
- Frequent medication titration to control blood pressure that was previously well controlled
- Sudden onset or increase in proteinuria

^{*} SI Pre E with and without severe features (similar diagnostic criteria as Pre E)

CASE #1- DIAGNOSIS?

38 yo G2P1001 hispanic female presents for prenatal care at 13 weeks gestation. Her OB history is significant for one previous c-section. Her PMH is significant for TIA in October 2019, maternal obesity and Factor V Leiden mutation.

Ultrasound evaluation reveals mono-di twin gestation. Prenatal vitals for the first 4 visits are:

Reading Date	GA	Prenatal Vitals	Urine Albumin/Glucose	Prenatal	Presentation
11/11/19	13w6d	135/86 / 178 lb 3.2 oz (80.8 kg) / 89	Trace / Negative / Negative / Trace / Negative / Negative	/ 148/155	TRANSVERSE
12/2/19	16w6d	137/81 / 183 lb (83 kg) / 78	′		
12/9/19	17w6d	154/89 † / 182 lb 9.6 o (82.8 kg) / 73	z	/ 138/144 / Present	
12/9/19	17w6d	135/91 ! //71			
TWG: 5 lb 9.6 oz (2.5	54 kg)	Pregravid weight: 177 lb	(80.3 kg)	Height: 157.5 cm (5' 2.01")	

RECOGNIZE THE RISK FACTORS

Box 1. Risk Factors for Preeclampsia

Nulliparity

Multifetal gestations

Preeclampsia in a previous pregnancy

Chronic hypertension

Pregestational diabetes

Gestational diabetes

Thrombophilia

Systemic lupus erythematosus

Prepregnancy body mass index greater than 30

Antiphospholipid antibody syndrome

Maternal age 35 years or older

Kidney disease

Assisted reproductive technology

Obstructive sleep apnea

ACOG Practice Bulletin, Number 202

CASE#1

38 yo G2P1001 hispanic female presents for prenatal care at 13 weeks gestation. Her OB history is significant for one previous c-section. Her PMH is significant for TIA in October 2019, maternal obesity (BMI 33) and Factor V Leiden mutation.

Ultrasound evaluation reveals mono-di twin gestation. Prepatal vitals for the first 4 visits are:

GA	Prenatal Vitals	Urine Albumin/Glucose	Prenatal	Presentation
13w6d	135/86 / 178 lb 3.2 oz (80.8 kg) / 89	Trace / Negative / Negative / Trace / Negative / Negative	/ 148/155	TRANSVERSE
16w6d	137/81 / 183 lb (83 kg) /	,		
17w6d	154/89 1 182 lb 9.6 oz (82.8 kg) / 78	Z	/ 138/144 / Present	
17w6d	135/91 ! /// 71			
	16w6d 17w6d	16w6d 137/81 / 183 lb (83 kg) / 78 17w6d 154/89 1 182 lb 9.6 oz (82.8 kg) / 78	(80.8 kg) / 89 Negative / Trace / Negative / Negative 16w6d 137/81 / 183 lb (83 kg) / 78 17w6d 154/89 182 lb 9.6 oz (82.8 kg) / 78	(80.8 kg) / 89 Negative / Trace / Negative / Negative / Negative 16w6d 137/81 / 183 lb (83 kg) / 78 17w6d 154/89 1 X 182 lb 9.6 oz / 138/144 / Present (82.8 kg) / 78

CASE #1

- Diagnosis CHTN
- Initial PIH panel including P/C ratio (< 0.30) are normal

At 31 weeks gestation her blood pressures are noted to be 174/101, 165/97, 170/100. Her P/C ratio is 0.65. What is her new diagnosis?

CASE #2 - DIAGNOSIS

23 yo G2P0010 presents to prenatal care at 11 weeks gestation.

PMH: Crohn's disease

PSH: partial bowel resection in 2018

PNC: IUGR, normal testing

She is scheduled for IOL at 39 weeks. Pt delivers via pLTCS 2/2 arrest of labor. On POD 1 the pt reports persistent HA. Vitals are:

0500 0457	BP (!) 146/103 (!) 143/99	Temp —	Temp src —	Pulse 78 72	Resp 18 18	SpO2
0455	(!) 160/101	98.6 °F (37 °C)	Oral	82	18	_
0208	140/70	_	_	71	_	_
0117	(!) 142/104	98 °F (36.7 °C)	Oral	76	18	98 %
0110	(!) 168/113	98 °F (36.7 °C)	Oral	71	18	98 %
2050	137/90	97.8 °F (36.6 °C)	Oral	87	18	98 %
1615	137/83	97.5 °F (36.4 °C)	Oral	89	18	98 %
1101	136/84	97.4 °F (36.3 °C)	Oral	83	18	98 %
0719	131/78	97.9 °F (36.6 °C)	Oral	79	18	98 %

INPATIENT MANAGEMENT





READINESS

Every Unit

- Standards for early warning signs, diagnostic criteria, monitoring and treatment of severe preeclampsia/eclampsia (include order sets and algorithms)
- Unit education on protocols, unit-based drills (with post-drill debriefs)
- Process for timely triage and evaluation of pregnant and postpartum women with hypertension including ED and outpatient areas
- Rapid access to medications used for severe hypertension/eclampsia: Medications should be stocked and immediately available on L&D and in other areas where patients may be treated. Include brief guide for administration and dosage.
- System plan for escalation, obtaining appropriate consultation, and maternal transport, as needed



RECOGNITION & PREVENTION


Every Patient

- Standard protocol for measurement and assessment of BP and urine protein for all pregnant and postpartum women
- Standard response to maternal early warning signs including listening to and investigating patient symptoms and assessment of labs (e.g. CBC with platelets, AST and ALT)
- Facility-wide standards for educating prenatal and postpartum women on signs and symptoms of hypertension and preeclampsia

PATIENT SAFETY BUNDLE


Hypertension

PREGNANCY IS A STRESS TEST



Delivery is NOT the finish line!

TIMING OF MATERNAL DEATHS




DELIVERY IS NOT THE FINISH LINE!




- The patient and your team need to understand the diagnosis
 - Elevated BP is not a diagnosis
- Specific discharge instructions
- Customized postpartum follow up
 - BP check in one week
- Clinic team should know the questions to ask


CARE COORDINATION




TEAM COMMUNICATION

Staff Message







CONTINUITY OF CARE - HTW







- Medicaid patients should autoenroll
- Patients can contact TMHP

IS THE PATIENT LIKELY TO BECOME PREGNANT AGAIN?



- Calcium Channel Blocker (CCB)
- Thiazide diuretic

*Beta-blockers are NOT first line!

- Angiotensin-converting enzyme inhibitor (ACEI)/ Angiotensin receptor blocker (ARB)
- CCB
- Thiazide diuretic

WHY?

 Both JNC8 and AHA recommend CCBs, thiazides, or ACEI/ARBs first line.

get

pregnant

again

If patient may get pregnant again, ACOG recommends against ACEI/

PHARMACY



WHAT'S COVERED UNDER HTW?

*No beta-blockers!

Not Likely to Get Pregnant Again

May Become Pregnant Again

ACEI

Lisinopril

Benazepril

Enalapril

Quinapril

Fosinopril 40 mg, Ramipril 10 mg (PA for other strengths)* ARB

requires
Prior
Authorizatio

CCBs

Nifedipine ER

Diltiazem ER

Verapamil IR and ER


Amlodipine 10 mg, Felodipine ER 10 mg (PA for other strengths)* Thiazid

20

Hydrochlorothiazi de (HCTZ)

PHARMACY





QUESTIONS?